Mirum Pharmaceuticals, Inc. (MIRM) 10-Year Financial Performance & Capital Metrics

MIRM •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

AboutMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.Show more

Revenue $521M +54.7%
EBITDA -$22M +65.4%
Net Income -$23M +73.4%
EPS (Diluted) -0.47 +74.6%
Gross Margin 80.77% +6.6%
EBITDA Margin -4.25% +77.6%
Operating Margin -4.25% +83.7%
Net Margin -4.48% +82.8%
ROE -8.65% +76.7%
ROIC -5.06% +77.2%
Debt/Equity 1.01 -28.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Expensive at 14.7x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y89.13%

TTM54.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM73.57%

ROCE

10Y Avg-36.41%

5Y Avg-33.41%

3Y Avg-15.12%

Latest-3.75%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	0	0	19.14M	77.06M	186.37M	336.89M	521.31M
Revenue Growth %	-	-	-	-	302.66%	141.85%	80.76%	54.74%
Cost of Goods Sold+	0	324K	623K	1.9M	12.37M	47.04M	81.64M	100.24M
COGS % of Revenue	-	-	-	9.94%	16.06%	25.24%	24.23%	19.23%
Gross Profit+	0	-324K	-623K	17.23M	64.69M	139.34M	255.25M	421.07M
Gross Margin %	-	-	-	90.06%	83.94%	74.76%	75.77%	80.77%
Gross Profit Growth %	-	-	-92.28%	2866.45%	275.33%	115.4%	83.19%	64.97%
Operating Expenses+	2.92M	54.74M	103.67M	190.65M	195.91M	248.49M	342.85M	443.21M
OpEx % of Revenue	-	-	-	996.18%	254.22%	133.33%	101.77%	85.02%
Selling, General & Admin	585K	11.75M	22.69M	59.22M	89.07M	145.88M	202.22M	257.03M
SG&A % of Revenue	-	-	-	309.44%	115.58%	78.27%	60.03%	49.3%
Research & Development	2.33M	42.99M	81.61M	131.43M	106.84M	102.61M	140.63M	186.18M
R&D % of Revenue	-	-	-	686.74%	138.64%	55.06%	41.74%	35.71%
Other Operating Expenses	0	-21K	-623K	0	0	0	0	0
Operating Income+	-2.92M	-54.74M	-104.3M	-173.41M	-131.22M	-109.15M	-87.61M	-22.14M
Operating Margin %	-	-	-	-906.12%	-170.28%	-58.57%	-26%	-4.25%
Operating Income Growth %	-	-1777.33%	-90.52%	-66.27%	24.33%	16.82%	19.74%	74.73%
EBITDA+	1.46M	-54.42M	-103.67M	-172.44M	-127.98M	-98.33M	-63.98M	-22.14M
EBITDA Margin %	-	-	-	-901.02%	-166.08%	-52.76%	-18.99%	-4.25%
EBITDA Growth %	-	-3832.44%	-90.51%	-66.33%	25.78%	23.17%	34.93%	65.4%
D&A (Non-Cash Add-back)	4.37M	324K	623K	975K	3.24M	10.83M	23.63M	0
EBIT	-17.33M	-52.53M	-102.93M	-66.36M	-126.09M	-147.32M	-72.6M	0
Net Interest Income+	0	2.23M	1.22M	-17.22M	-12.12M	-1.37M	-519K	0
Interest Income	87K	2.23M	1.56M	366K	3.86M	13.73M	13.79M	12.73M
Interest Expense	0	0	335K	17.59M	15.98M	15.11M	14.31M	-14.39M
Other Income/Expense	-14.43M	2.21M	1.03M	89.46M	-10.85M	-53.27M	694K	709K
Pretax Income+	-17.35M	-52.53M	-103.26M	-83.95M	-142.07M	-162.42M	-86.91M	-21.43M
Pretax Margin %	-	-	-	-438.66%	-184.36%	-87.15%	-25.8%	-4.11%
Income Tax+	0	21K	6K	37K	-6.41M	991K	1.03M	1.94M
Effective Tax Rate %	100%	100.04%	100.01%	100.04%	95.49%	100.61%	101.19%	109.04%
Net Income+	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Net Margin %	-	-	-	-438.85%	-176.05%	-87.68%	-26.1%	-4.48%
Net Income Growth %	-	-202.93%	-96.51%	18.67%	-61.53%	-20.45%	46.18%	73.43%
Net Income (Continuing)	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.75	-2.29	-4.09	-2.77	-4.02	-4.00	-1.85	-0.47
EPS Growth %	-	-205.33%	-78.6%	32.27%	-45.13%	0.5%	53.75%	74.59%
EPS (Basic)	-0.75	-2.29	-4.09	-2.77	-4.01	-4.00	-1.85	-0.47
Diluted Shares Outstanding	22.99M	22.99M	25.25M	30.32M	33.98M	40.89M	47.52M	50.2M
Basic Shares Outstanding	22.99M	22.99M	25.25M	30.32M	33.84M	40.89M	47.52M	50.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	51.98M	119.36M	236.35M	166.59M	190.22M	387.54M	392.79M	549.68M
Cash & Short-Term Investments	51.96M	116.66M	231.82M	156.54M	151.72M	286.33M	280.31M	383.33M
Cash Only	51.96M	11.97M	142.09M	31.34M	28M	286.33M	222.5M	296.68M
Short-Term Investments	0	104.69M	89.73M	125.2M	123.72M	0	57.81M	86.64M
Accounts Receivable	0	0	0	3.27M	23.99M	67.97M	78.29M	123.33M
Days Sales Outstanding	-	-	-	62.31	113.65	133.11	84.82	86.35
Inventory	0	0	0	1.51M	5.57M	22.31M	22.4M	24.89M
Days Inventory Outstanding	-	-	-	290.2	164.15	173.13	100.16	90.62
Other Current Assets	12K	0	0	0	8.95M	10.94M	11.78M	18.14M
Total Non-Current Assets+	0	27.35M	4.51M	128.06M	162.68M	259.08M	277.97M	293.13M
Property, Plant & Equipment	0	3.73M	3.24M	2.55M	2.35M	1.99M	9.81M	0
Fixed Asset Turnover	-	-	-	7.51x	32.86x	93.66x	34.33x	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	18.74M	58.95M	252.93M	249.82M	260.92M
Long-Term Investments	0	23.29M	0	4.98M	0	0	12.53M	8.11M
Other Non-Current Assets	0	324K	1.27M	101.79M	101.38M	4.17M	5.81M	24.1M
Total Assets+	51.98M	146.71M	240.86M	294.65M	352.91M	646.62M	670.75M	842.81M
Asset Turnover	-	-	-	0.06x	0.22x	0.29x	0.50x	0.62x
Asset Growth %	-	182.27%	64.17%	22.33%	19.77%	83.23%	3.73%	25.65%
Total Current Liabilities+	2.45M	13.08M	18.46M	42.6M	64.73M	87.06M	126.55M	205.8M
Accounts Payable	269K	3.35M	3.15M	9.17M	8.69M	7.42M	14.62M	9.61M
Days Payables Outstanding	-	3.78K	1.85K	1.76K	256.33	57.54	65.35	35.01
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	15K	2.22M	6.07M	11.98M	15.75M	20.94M	32.25M	196.19M
Current Ratio	21.22x	9.13x	12.80x	3.91x	2.94x	4.45x	3.10x	2.67x
Quick Ratio	21.22x	9.13x	12.80x	3.88x	2.85x	4.19x	2.93x	2.55x
Cash Conversion Cycle	-	-	-	-1.41K	21.47	248.7	119.62	141.96
Total Non-Current Liabilities+	59.85M	3.29M	50.31M	131.84M	146.14M	310.89M	318.56M	322.32M
Long-Term Debt	0	0	0	0	0	306.42M	308.08M	317.31M
Capital Lease Obligations	0	3.25M	2.63M	1.9M	1.26M	617K	7.97M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.85M	36K	29K	17K	4.53M	3.85M	2.51M	5.01M
Total Liabilities	62.3M	16.36M	68.77M	174.44M	210.87M	397.95M	445.11M	528.12M
Total Debt+	0	3.65M	3.26M	2.61M	2.19M	308.14M	317.76M	317.31M
Net Debt	-51.96M	-8.32M	-138.82M	-28.73M	-25.82M	21.82M	95.26M	20.63M
Debt / Equity	-	0.03x	0.02x	0.02x	0.02x	1.24x	1.41x	1.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-35.64x	-	-	-	-	-	-	-
Interest Coverage	-	-	-311.33x	-9.86x	-8.21x	-7.23x	-6.12x	-
Total Equity+	-10.32M	130.35M	172.09M	120.21M	142.04M	248.67M	225.64M	314.69M
Equity Growth %	-	1362.7%	32.03%	-30.15%	18.16%	75.07%	-9.26%	39.47%
Book Value per Share	-0.45	5.67	6.82	3.96	4.18	6.08	4.75	6.27
Total Shareholders' Equity	-10.32M	130.35M	172.09M	120.21M	142.04M	248.67M	225.64M	314.69M
Common Stock	6.99M	2K	3K	3K	4K	5K	5K	5K
Retained Earnings	-17.35M	-69.9M	-173.17M	-257.16M	-392.82M	-556.24M	-644.18M	-667.54M
Treasury Stock	66.81M	0	0	0	0	0	0	0
Accumulated OCI	-66.84M	129K	83K	-35K	-217K	1.64M	-373K	351K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-373K	-39.36M	-89.08M	-132.76M	-120.14M	-70.94M	10.32M	55.83M
Operating CF Margin %	-	-	-	-693.69%	-155.9%	-38.07%	3.06%	10.71%
Operating CF Growth %	-	-10452.82%	-126.3%	-49.04%	9.51%	40.95%	114.55%	440.7%
Net Income	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Depreciation & Amortization	0	324K	623K	975K	3.68M	10.83M	23.63M	24.24M
Stock-Based Compensation	51K	6.07M	12.55M	23.09M	27.01M	35.02M	48.44M	71.42M
Deferred Taxes	0	0	72K	595K	-6.58M	0	0	0
Other Non-Cash Items	12.09M	-326K	335K	-90.41M	12.47M	69.26M	3.6M	-16.48M
Working Capital Changes	2.44M	7.12M	611K	16.98M	-21.05M	-22.64M	22.59M	0
Change in Receivables	0	0	0	0	-20.73M	-43.97M	-11.43M	-48.05M
Change in Inventory	0	0	0	-495K	-3.45M	-4.39M	-3.17M	-8.45M
Change in Payables	2.45M	10.06M	3.68M	22.66M	7.64M	30.78M	40.31M	50.1M
Cash from Investing+	-7.5M	-127.78M	37.87M	48.55M	7.7M	-107.2M	-90.13M	-23.95M
Capital Expenditures	-7.5M	-281K	-225K	-19.02M	-278K	-109K	-993K	-954K
CapEx % of Revenue	-	-	-	99.4%	0.36%	0.06%	0.29%	0.18%
Acquisitions	0	127.5M	-38.1M	-19M	-7.98M	-212.76M	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	-11.25M	-127.5M	38.1M	127M	7.98M	-20M	-20M	0
Cash from Financing+	59.84M	127.18M	181.29M	73.47M	109.09M	336.6M	17.7M	40.14M
Debt Issued (Net)	50K	0	0	0	0	305.3M	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	0	0	49.42M	66.55M	1.72M	-185.39M	0	40.14M
Net Change in Cash	51.96M	-39.99M	130.12M	-10.75M	-3.34M	158.32M	-63.4M	75.24M
Free Cash Flow+	-7.87M	-39.64M	-89.3M	-151.78M	-120.41M	-91.05M	9.33M	54.87M
FCF Margin %	-	-	-	-793.09%	-156.26%	-48.85%	2.77%	10.53%
FCF Growth %	-	-403.53%	-125.26%	-69.97%	20.67%	24.38%	110.25%	488.01%
FCF per Share	-0.34	-1.72	-3.54	-5.01	-3.54	-2.23	0.20	1.09
FCF Conversion (FCF/Net Income)	0.02x	0.75x	0.86x	1.58x	0.89x	0.43x	-0.12x	-2.39x
Interest Paid	0	0	0	0	0	6.82M	12.65M	0
Taxes Paid	0	21K	11K	0	0	125K	1M	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-87.57%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%	-8.65%
Return on Invested Capital (ROIC)	-	-137.45%	-100.74%	-208.5%	-94.76%	-42.34%	-22.22%	-5.06%
Gross Margin	-	-	-	90.06%	83.94%	74.76%	75.77%	80.77%
Net Margin	-	-	-	-438.85%	-176.05%	-87.68%	-26.1%	-4.48%
Debt / Equity	-	0.03x	0.02x	0.02x	0.02x	1.24x	1.41x	1.01x
Interest Coverage	-	-	-311.33x	-9.86x	-8.21x	-7.23x	-6.12x	-
FCF Conversion	0.02x	0.75x	0.86x	1.58x	0.89x	0.43x	-0.12x	-2.39x
Revenue Growth	-	-	-	-	302.66%	141.85%	80.76%	54.74%

US Stock Screener

...

Mirum Pharmaceuticals, Inc. (MIRM) 10-Year Financial Performance & Capital Metrics

MIRM •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

Revenue $521M +54.7%
EBITDA -$22M +65.4%
Net Income -$23M +73.4%
EPS (Diluted) -0.47 +74.6%
Gross Margin 80.77% +6.6%
EBITDA Margin -4.25% +77.6%
Operating Margin -4.25% +83.7%
Net Margin -4.48% +82.8%
ROE -8.65% +76.7%
ROIC -5.06% +77.2%
Debt/Equity 1.01 -28.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Expensive at 14.7x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y89.13%

TTM54.74%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM73.57%

ROCE

10Y Avg-36.41%

5Y Avg-33.41%

3Y Avg-15.12%

Latest-3.75%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	0	0	19.14M	77.06M	186.37M	336.89M	521.31M
Revenue Growth %	-	-	-	-	302.66%	141.85%	80.76%	54.74%
Cost of Goods Sold+	0	324K	623K	1.9M	12.37M	47.04M	81.64M	100.24M
COGS % of Revenue	-	-	-	9.94%	16.06%	25.24%	24.23%	19.23%
Gross Profit+	0	-324K	-623K	17.23M	64.69M	139.34M	255.25M	421.07M
Gross Margin %	-	-	-	90.06%	83.94%	74.76%	75.77%	80.77%
Gross Profit Growth %	-	-	-92.28%	2866.45%	275.33%	115.4%	83.19%	64.97%
Operating Expenses+	2.92M	54.74M	103.67M	190.65M	195.91M	248.49M	342.85M	443.21M
OpEx % of Revenue	-	-	-	996.18%	254.22%	133.33%	101.77%	85.02%
Selling, General & Admin	585K	11.75M	22.69M	59.22M	89.07M	145.88M	202.22M	257.03M
SG&A % of Revenue	-	-	-	309.44%	115.58%	78.27%	60.03%	49.3%
Research & Development	2.33M	42.99M	81.61M	131.43M	106.84M	102.61M	140.63M	186.18M
R&D % of Revenue	-	-	-	686.74%	138.64%	55.06%	41.74%	35.71%
Other Operating Expenses	0	-21K	-623K	0	0	0	0	0
Operating Income+	-2.92M	-54.74M	-104.3M	-173.41M	-131.22M	-109.15M	-87.61M	-22.14M
Operating Margin %	-	-	-	-906.12%	-170.28%	-58.57%	-26%	-4.25%
Operating Income Growth %	-	-1777.33%	-90.52%	-66.27%	24.33%	16.82%	19.74%	74.73%
EBITDA+	1.46M	-54.42M	-103.67M	-172.44M	-127.98M	-98.33M	-63.98M	-22.14M
EBITDA Margin %	-	-	-	-901.02%	-166.08%	-52.76%	-18.99%	-4.25%
EBITDA Growth %	-	-3832.44%	-90.51%	-66.33%	25.78%	23.17%	34.93%	65.4%
D&A (Non-Cash Add-back)	4.37M	324K	623K	975K	3.24M	10.83M	23.63M	0
EBIT	-17.33M	-52.53M	-102.93M	-66.36M	-126.09M	-147.32M	-72.6M	0
Net Interest Income+	0	2.23M	1.22M	-17.22M	-12.12M	-1.37M	-519K	0
Interest Income	87K	2.23M	1.56M	366K	3.86M	13.73M	13.79M	12.73M
Interest Expense	0	0	335K	17.59M	15.98M	15.11M	14.31M	-14.39M
Other Income/Expense	-14.43M	2.21M	1.03M	89.46M	-10.85M	-53.27M	694K	709K
Pretax Income+	-17.35M	-52.53M	-103.26M	-83.95M	-142.07M	-162.42M	-86.91M	-21.43M
Pretax Margin %	-	-	-	-438.66%	-184.36%	-87.15%	-25.8%	-4.11%
Income Tax+	0	21K	6K	37K	-6.41M	991K	1.03M	1.94M
Effective Tax Rate %	100%	100.04%	100.01%	100.04%	95.49%	100.61%	101.19%	109.04%
Net Income+	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Net Margin %	-	-	-	-438.85%	-176.05%	-87.68%	-26.1%	-4.48%
Net Income Growth %	-	-202.93%	-96.51%	18.67%	-61.53%	-20.45%	46.18%	73.43%
Net Income (Continuing)	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.75	-2.29	-4.09	-2.77	-4.02	-4.00	-1.85	-0.47
EPS Growth %	-	-205.33%	-78.6%	32.27%	-45.13%	0.5%	53.75%	74.59%
EPS (Basic)	-0.75	-2.29	-4.09	-2.77	-4.01	-4.00	-1.85	-0.47
Diluted Shares Outstanding	22.99M	22.99M	25.25M	30.32M	33.98M	40.89M	47.52M	50.2M
Basic Shares Outstanding	22.99M	22.99M	25.25M	30.32M	33.84M	40.89M	47.52M	50.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	51.98M	119.36M	236.35M	166.59M	190.22M	387.54M	392.79M	549.68M
Cash & Short-Term Investments	51.96M	116.66M	231.82M	156.54M	151.72M	286.33M	280.31M	383.33M
Cash Only	51.96M	11.97M	142.09M	31.34M	28M	286.33M	222.5M	296.68M
Short-Term Investments	0	104.69M	89.73M	125.2M	123.72M	0	57.81M	86.64M
Accounts Receivable	0	0	0	3.27M	23.99M	67.97M	78.29M	123.33M
Days Sales Outstanding	-	-	-	62.31	113.65	133.11	84.82	86.35
Inventory	0	0	0	1.51M	5.57M	22.31M	22.4M	24.89M
Days Inventory Outstanding	-	-	-	290.2	164.15	173.13	100.16	90.62
Other Current Assets	12K	0	0	0	8.95M	10.94M	11.78M	18.14M
Total Non-Current Assets+	0	27.35M	4.51M	128.06M	162.68M	259.08M	277.97M	293.13M
Property, Plant & Equipment	0	3.73M	3.24M	2.55M	2.35M	1.99M	9.81M	0
Fixed Asset Turnover	-	-	-	7.51x	32.86x	93.66x	34.33x	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	18.74M	58.95M	252.93M	249.82M	260.92M
Long-Term Investments	0	23.29M	0	4.98M	0	0	12.53M	8.11M
Other Non-Current Assets	0	324K	1.27M	101.79M	101.38M	4.17M	5.81M	24.1M
Total Assets+	51.98M	146.71M	240.86M	294.65M	352.91M	646.62M	670.75M	842.81M
Asset Turnover	-	-	-	0.06x	0.22x	0.29x	0.50x	0.62x
Asset Growth %	-	182.27%	64.17%	22.33%	19.77%	83.23%	3.73%	25.65%
Total Current Liabilities+	2.45M	13.08M	18.46M	42.6M	64.73M	87.06M	126.55M	205.8M
Accounts Payable	269K	3.35M	3.15M	9.17M	8.69M	7.42M	14.62M	9.61M
Days Payables Outstanding	-	3.78K	1.85K	1.76K	256.33	57.54	65.35	35.01
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	15K	2.22M	6.07M	11.98M	15.75M	20.94M	32.25M	196.19M
Current Ratio	21.22x	9.13x	12.80x	3.91x	2.94x	4.45x	3.10x	2.67x
Quick Ratio	21.22x	9.13x	12.80x	3.88x	2.85x	4.19x	2.93x	2.55x
Cash Conversion Cycle	-	-	-	-1.41K	21.47	248.7	119.62	141.96
Total Non-Current Liabilities+	59.85M	3.29M	50.31M	131.84M	146.14M	310.89M	318.56M	322.32M
Long-Term Debt	0	0	0	0	0	306.42M	308.08M	317.31M
Capital Lease Obligations	0	3.25M	2.63M	1.9M	1.26M	617K	7.97M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.85M	36K	29K	17K	4.53M	3.85M	2.51M	5.01M
Total Liabilities	62.3M	16.36M	68.77M	174.44M	210.87M	397.95M	445.11M	528.12M
Total Debt+	0	3.65M	3.26M	2.61M	2.19M	308.14M	317.76M	317.31M
Net Debt	-51.96M	-8.32M	-138.82M	-28.73M	-25.82M	21.82M	95.26M	20.63M
Debt / Equity	-	0.03x	0.02x	0.02x	0.02x	1.24x	1.41x	1.01x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-35.64x	-	-	-	-	-	-	-
Interest Coverage	-	-	-311.33x	-9.86x	-8.21x	-7.23x	-6.12x	-
Total Equity+	-10.32M	130.35M	172.09M	120.21M	142.04M	248.67M	225.64M	314.69M
Equity Growth %	-	1362.7%	32.03%	-30.15%	18.16%	75.07%	-9.26%	39.47%
Book Value per Share	-0.45	5.67	6.82	3.96	4.18	6.08	4.75	6.27
Total Shareholders' Equity	-10.32M	130.35M	172.09M	120.21M	142.04M	248.67M	225.64M	314.69M
Common Stock	6.99M	2K	3K	3K	4K	5K	5K	5K
Retained Earnings	-17.35M	-69.9M	-173.17M	-257.16M	-392.82M	-556.24M	-644.18M	-667.54M
Treasury Stock	66.81M	0	0	0	0	0	0	0
Accumulated OCI	-66.84M	129K	83K	-35K	-217K	1.64M	-373K	351K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-373K	-39.36M	-89.08M	-132.76M	-120.14M	-70.94M	10.32M	55.83M
Operating CF Margin %	-	-	-	-693.69%	-155.9%	-38.07%	3.06%	10.71%
Operating CF Growth %	-	-10452.82%	-126.3%	-49.04%	9.51%	40.95%	114.55%	440.7%
Net Income	-17.35M	-52.55M	-103.27M	-83.99M	-135.66M	-163.41M	-87.94M	-23.36M
Depreciation & Amortization	0	324K	623K	975K	3.68M	10.83M	23.63M	24.24M
Stock-Based Compensation	51K	6.07M	12.55M	23.09M	27.01M	35.02M	48.44M	71.42M
Deferred Taxes	0	0	72K	595K	-6.58M	0	0	0
Other Non-Cash Items	12.09M	-326K	335K	-90.41M	12.47M	69.26M	3.6M	-16.48M
Working Capital Changes	2.44M	7.12M	611K	16.98M	-21.05M	-22.64M	22.59M	0
Change in Receivables	0	0	0	0	-20.73M	-43.97M	-11.43M	-48.05M
Change in Inventory	0	0	0	-495K	-3.45M	-4.39M	-3.17M	-8.45M
Change in Payables	2.45M	10.06M	3.68M	22.66M	7.64M	30.78M	40.31M	50.1M
Cash from Investing+	-7.5M	-127.78M	37.87M	48.55M	7.7M	-107.2M	-90.13M	-23.95M
Capital Expenditures	-7.5M	-281K	-225K	-19.02M	-278K	-109K	-993K	-954K
CapEx % of Revenue	-	-	-	99.4%	0.36%	0.06%	0.29%	0.18%
Acquisitions	0	127.5M	-38.1M	-19M	-7.98M	-212.76M	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	-11.25M	-127.5M	38.1M	127M	7.98M	-20M	-20M	0
Cash from Financing+	59.84M	127.18M	181.29M	73.47M	109.09M	336.6M	17.7M	40.14M
Debt Issued (Net)	50K	0	0	0	0	305.3M	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	0	0	49.42M	66.55M	1.72M	-185.39M	0	40.14M
Net Change in Cash	51.96M	-39.99M	130.12M	-10.75M	-3.34M	158.32M	-63.4M	75.24M
Free Cash Flow+	-7.87M	-39.64M	-89.3M	-151.78M	-120.41M	-91.05M	9.33M	54.87M
FCF Margin %	-	-	-	-793.09%	-156.26%	-48.85%	2.77%	10.53%
FCF Growth %	-	-403.53%	-125.26%	-69.97%	20.67%	24.38%	110.25%	488.01%
FCF per Share	-0.34	-1.72	-3.54	-5.01	-3.54	-2.23	0.20	1.09
FCF Conversion (FCF/Net Income)	0.02x	0.75x	0.86x	1.58x	0.89x	0.43x	-0.12x	-2.39x
Interest Paid	0	0	0	0	0	6.82M	12.65M	0
Taxes Paid	0	21K	11K	0	0	125K	1M	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-87.57%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%	-8.65%
Return on Invested Capital (ROIC)	-	-137.45%	-100.74%	-208.5%	-94.76%	-42.34%	-22.22%	-5.06%
Gross Margin	-	-	-	90.06%	83.94%	74.76%	75.77%	80.77%
Net Margin	-	-	-	-438.85%	-176.05%	-87.68%	-26.1%	-4.48%
Debt / Equity	-	0.03x	0.02x	0.02x	0.02x	1.24x	1.41x	1.01x
Interest Coverage	-	-	-311.33x	-9.86x	-8.21x	-7.23x	-6.12x	-
FCF Conversion	0.02x	0.75x	0.86x	1.58x	0.89x	0.43x	-0.12x	-2.39x
Revenue Growth	-	-	-	-	302.66%	141.85%	80.76%	54.74%

Mirum Pharmaceuticals, Inc. (MIRM) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare MIRM vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Mirum Pharmaceuticals, Inc. (MIRM) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare MIRM vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios